Cancer researchers are generating mounds of molecular data
on tumor biology.
Not exact matches
We're also making progress
on our liquid biopsy program since our last update, including the recently announced collaboration with Memorial Sloan Kettering Cancer Center, which is focused
on furthering the basic understanding of the
biology of circulating
tumor DNA, or ctDNA, in different cancer types.
«The
tumor cells are smart,» said Wei Guo, co-corresponding author
on the study and a professor of
biology in Penn's School of Arts and Sciences.
In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused
on developing a deep understanding of
tumor immune
biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.
«If you can get a better handle
on the
biology of the primary
tumor, and the elements of the
tumor that may be more or less dangerous, then you don't need to worry about testing every single metastasis for treatment decisions.»
Dr. Yaffe's research focuses
on the
biology of the complex signaling pathways that cells use to respond to DNA damage and inflammation, particularly the role of protein kinases and modular binding domains in
tumor development and anti-cancer therapeutics.
Future oncologists will need to have a much deeper understanding of
tumor biology on a molecular level than their predecessors.
By shedding light
on subtle distinctions in
tumor biology, these findings offer clues to designing more effective anticancer treatments to precisely target
tumors in individual patients.
We are just beginning to understand the
biology underpinning NSAID use
on the
tumor's molecular pathways, and it's very exciting.»
Of note, the current study is part of a recent surge in NYU Langone findings
on pancreatic cancer, including studies
on how first - responder cells turn off the immune response, the role of the drug nab - paclitaxel in
tumor biology, cancer cells» unique fuel sources, and how immune cell infighting drives the disease.
NEW YORK and SEATTLE — April 5, 2018 — The Cancer Research Institute (CRI), Institute for Systems
Biology (ISB) and Sage Bionetworks — three organizations
on the forefront of cancer immunotherapy, systems
biology and bioinformatics — today announced the release of the Cancer Research Institute iAtlas, a comprehensive web - based tool that allows oncologists and researchers to study and analyze interactions between
tumors and the immune microenvironment.
Although extensive efforts have been devoted to understanding the effect of hypoxia
on tumor progression, two areas of
tumor biology remain unclear.
In addition to her expertise in
tumor biology and a broad network of connections with leading scientists and clinicians in cancer research and clinical oncology, Dr. Almog has extensive hands -
on experience with a variety of techniques ranging from the molecular level (DNA, RNA and proteins) to tissue, organ and mouse models in cancer
biology, as well as extensive experience in project management and program coordination.
During his 11 years of extensive work experience in the fields of cell and cancer
biology (including work
on the famous
tumor suppressor gene BRCA1), and biochemistry he has successfully published in peer - reviewed journals such as Molecular and Cell
Biology and Cancer Research.
In my own lab here at Indiana University School of Medicine, I am bringing some of those chemical
biology techniques to bear
on problems in eye disease and we continue to work
on tumors of the eye, but we also developed a major focus
on neovascular eye diseases, including wet, age - related macular degeneration (AMD).
CSC hypothesis has resulted in incredible impact
on the understanding and insight into
tumor biology.
Using expertise in genomics and cell
biology, Dr. Pillai is looking forward to expanding his research in the field of
Tumor Immunology, with focus
on Breast Cancer.
Michael Nolan, assistant professor of radiation oncology and
biology, received $ 23,060 for a study
on using enhanced ethanol ablation, or direct ethanol injections to reduce
tumors, as a lower - cost treatment for oral cancer.
Michael Nolan, assistant professor of radiation oncology and
biology, received $ 23,060 for a study
on using enhanced ethanol ablation, or direct ethanol injections to reduce
tumors, as a
In the last 10 years, we've invested just over $ 150,000 in seven studies focused specifically
on squamous cell carcinoma, melanoma, and sarcoid
tumor biology and treatment.